Assetmark Inc. Has $8.11 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Assetmark Inc. raised its holdings in Johnson & Johnson (NYSE:JNJ) by 2.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 51,728 shares of the company’s stock after purchasing an additional 1,060 shares during the quarter. Assetmark Inc.’s holdings in Johnson & Johnson were worth $8,108,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $4,071,642,000. Charles Schwab Investment Management Inc. lifted its holdings in Johnson & Johnson by 1.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 15,945,533 shares of the company’s stock worth $2,483,532,000 after buying an additional 241,799 shares during the period. California Public Employees Retirement System lifted its holdings in Johnson & Johnson by 4.9% during the 4th quarter. California Public Employees Retirement System now owns 10,620,264 shares of the company’s stock worth $1,664,620,000 after buying an additional 498,647 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Johnson & Johnson by 10.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 10,169,190 shares of the company’s stock worth $1,593,908,000 after buying an additional 975,485 shares during the period. Finally, Clearbridge Investments LLC lifted its holdings in Johnson & Johnson by 0.8% during the 4th quarter. Clearbridge Investments LLC now owns 6,285,184 shares of the company’s stock worth $985,140,000 after buying an additional 50,822 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of several recent research reports. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Bank of America cut their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research report on Wednesday. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, May 6th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $175.86.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $152.88 on Thursday. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97. The firm has a market capitalization of $367.93 billion, a price-to-earnings ratio of 9.57, a PEG ratio of 2.51 and a beta of 0.55. The business has a 50-day simple moving average of $151.73 and a 200 day simple moving average of $155.11. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.68 EPS. On average, research analysts anticipate that Johnson & Johnson will post 10.64 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. The ex-dividend date is Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.